Aryastha Life Sciences

Executive Summary

Aryastha Life Sciences is an Indian-based integrated drug discovery and development services company headquartered in Hyderabad. Founded in 2016, the company employs 200-500 personnel and offers end-to-end solutions from target identification to preclinical DMPK and toxicology. Its key differentiators include advanced iPSC-derived cardiac and hepatic models, enabling more predictive human-relevant assays. Aryastha focuses on oncology, immunology, and biologics, positioning itself as a cost-effective partner for global pharma and biotech firms seeking to accelerate their R&D pipelines. With the increasing trend of outsourcing preclinical services to India, Aryastha is well-placed to capture market share by combining scientific expertise with competitive pricing. The company's growth trajectory will likely be driven by expanding its platform capabilities and forging strategic partnerships. While Aryastha does not have its own drug pipeline, its service-based model provides recurring revenue and lower risk. The company may benefit from the growing demand for specialized preclinical models, particularly iPSC-based assays, as regulatory agencies encourage more physiologically relevant testing. However, as a private firm, visibility into financials and upcoming milestones is limited. Overall, Aryastha Life Sciences represents a compelling opportunity in the CRO space, with potential for steady expansion and margin improvement as it scales its operations.

Upcoming Catalysts (preview)

• Q3 2026Major Partnership with Top 20 Pharma Company40% success
• Q4 2026Launch of Organ-on-Chip Service Platform50% success
• Q2 2026Expansion of Laboratory Facilities in Hyderabad70% success